Shares of ResMed(NYSE: RMD) were jumping 7% as of 11:25 a.m. ET on Thursday after rising as much as 10.6% earlier in the morning. The solid gain came after the medical device maker announced results for its fiscal 2024 second quarter ended Dec. 31, 2023, following the market close on Wednesday.
What did investors like about ResMed's fiscal Q2 results?
ResMed reported Q2 revenue of $1.16 billion. This reflected a 12% year-over-year increase and was a little above the consensus Wall Street estimate.
The company posted earnings of $208.8 million, or $1.42 per diluted share, based on generally accepted accounting principles (GAAP). On a non-GAAP (adjusted) basis, ResMed's earnings came in at $277.3 million, or $1.88 per diluted share. This bottom-line amount was 13% higher than adjusted earnings recorded in the prior-year period. It also beat the average analysts' earnings estimate of $1.81 per share.
ResMed CEO Mick Farrell said in the press release announcing the latest results that the company delivered "strong double-digit growth" across the board with its products and services. The company's software-as-a-service (SaaS) revenue soared 24% year over year, largely as a result of ResMed's 2022 acquisition of German hospital software developer Medifox Dan.
Is ResMed stock a good pick to buy now?
ResMed's future appears to be bright. The company is expanding the commercialization of its latest CPAP machine, AirSense 11, into new geographical regions. It remains the clear leader in the sleep-related medical equipment market.
So is ResMed stock a good pick to buy? I like it overall but have one key reservation -- valuation. Shares currently trade at a forward earnings multiple of 24. That's somewhat steep, in my view, considering the level of growth the company is delivering. I think that ResMed could be a good stock to buy on a pullback, but not right now.
Should you invest $1,000 in ResMed right now?
Before you buy stock in ResMed, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and ResMed wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of January 22, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ResMed. The Motley Fool has a disclosure policy.
